Academy of Allergy & Asthma in Primary Care v. AMERIGROUP TENNESSEE, INC., dba Amerigroup Community Care

RECOMMENDED FOR PUBLICATION
Pursuant to Sixth Circuit I.O.P. 32.1(b)
File Name: 25a0280p.06
UNITED STATES COURT OF APPEALS
FOR THE SIXTH CIRCUIT
ACADEMY OF ALLERGY & ASTHMA IN PRIMARY CARE,
Plaintiff,
UNITED BIOLOGICS, LLC, dba United Allergy Services
Plaintiff-Appellant,
v.
AMERIGROUP TENNESSEE, INC., dba Amerigroup
Community Care; PHYSICIANS’ MEDICAL ENTERPRISES,
LLC, dba PME Communications, LLC; ALLERGY
ASSOCIATES, P.A., dba Allergy, Asthma and Sinus
Center, P.C.; NED DELOZIER,
Defendants - Appellees.
┐
│
│
│
│
│
│
│
│
│
│
│
│
│
│
│
┘
No. 24-5153
Appeal from the United States District Court for the Eastern District of Tennessee at Knoxville.
No. 3:19-cv-00180—Travis Randall McDonough, District Judge.
Argued: February 5, 2025
Decided and Filed: October 10, 2025
Before: SUTTON, Chief Judge; KETHLEDGE and MURPHY, Circuit Judges.
_________________
COUNSEL
ARGUED: Paul D. Clement, CLEMENT & MURPHY, PLLC, Alexandria, Virginia, Casey
Low, PILLSBURY WINTHROP SHAW PITTMAN LLP, Austin, Texas, for Appellant.
William J. Sheridan, REED SMITH LLP, Pittsburgh, Pennsylvania, for Appellee Amerigroup
Tennessee, Inc. John E. Winters, KRAMER RAYSON LLP, Knoxville, Tennessee, for
Appellees Physicians’ Medical Enterprises LLC, Allergy Associates P.A., and Ned DeLozier.
ON BRIEF: Paul D. Clement, Matthew D. Rowen, James Y. Xi, CLEMENT & MURPHY,
PLLC, Alexandria, Virginia, Casey Low, Dillon J. Ferguson, Michael H. Borofsky, Sarah Goetz,
PILLSBURY WINTHROP SHAW PITTMAN LLP, Austin, Texas, for Appellant. William J.
Sheridan, REED SMITH LLP, Pittsburgh, Pennsylvania, Raymond A. Cardozo, REED SMITH
>

-- 1 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 2
LLP, San Francisco, California, for Appellee Amerigroup Tennessee, Inc. John E. Winters,
Bryce E. Fitzgerald, KRAMER RAYSON LLP, Knoxville, Tennessee, for Appellees Physicians’
Medical Enterprises LLC, Allergy Associates P.A., and Ned DeLozier.
MURPHY, J., delivered the opinion of the court in which SUTTON, C.J., and
KETHLEDGE, J., concurred. KETHLEDGE, J. (pp. 42–43), delivered a separate concurring
opinion.
_________________
OPINION
_________________
MURPHY, Circuit Judge. The plaintiff in this case—which we will call “United
Allergy”—provides personnel and supplies to primary-care physicians so that the physicians
may offer allergy testing and immunotherapy to patients. United Allergy charges the physicians
a set fee for its goods and services, and the physicians, in turn, charge medical insurers for their
own allergy care. According to United Allergy, though, several insurers conspired with each
other and with the predominant allergy-care medical group to drive United Allergy and its
contracting physicians from the market. United Allergy brought two antitrust claims against the
insurers and medical group. Yet the antitrust laws permit plaintiffs to sue only if they have
suffered injuries “by reason of” an antitrust violation. 15 U.S.C. § 15(a). And the district court
dismissed United Allergy’s antitrust claims on the pleadings because it lacked “standing” to
invoke this provision. The court then rejected United Allergy’s state-law claims at the summary-
judgment stage.
We agree with the district court’s results. In the process, though, we must clarify the
nature of the antitrust inquiry. To sue under the antitrust laws, a plaintiff must show both that it
suffered an antitrust injury and that the defendant proximately caused the injury. United
Allergy’s suit flunks the latter element. Relying on proximate-causation principles, the Supreme
Court has held “that indirect purchasers who are two or more steps removed from [an antitrust]
violator in a distribution chain may not sue.” Apple Inc. v. Pepper, 587 U.S. 273, 279 (2019).
And the same rule should apply in reverse to indirect sellers for antitrust violations that a group
of buyers (like the insurers here) commit. United Allergy is also an indirect seller because it is
“two” “steps removed from” the insurers in the distribution chain. Id. The insurers directly

-- 2 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 3
bought from (and harmed) the primary-care physicians by allegedly conspiring to fix their
reimbursement rates and deny their claims. And that conduct harmed United Allergy only
indirectly because it led the physicians not to pay United Allergy’s fees and to end their
relationship. We thus affirm.
I
The district court dismissed this case in part at the pleading stage and in part at the
summary-judgment stage. When considering the claims that the district court rejected at the
pleading stage, we must rely on the factual allegations in United Allergy’s complaint. See
Blackwell v. Nocerini, 123 F.4th 479, 482 (6th Cir. 2024). And when considering the claims that
the district court rejected on summary judgment, we must rely on the facts that United Allergy
has supported with evidence. See Gambrel v. Knox County, 25 F.4th 391, 400 (6th Cir. 2022).
To describe the facts, then, we rely primarily on the complaint while adding some supplemental
(undisputed) information from the record.
A
Allergies affect millions of Americans. Some 30 to 40% of the population suffers from
seasonal hay fever (or “allergic rhinitis”) every spring and fall. Compl., R.103, PageID 2668.
This case concerns the medical services that treat allergies, the medical suppliers who provide
these services, and the third-party payors who pay for them on behalf of patients.
Services. To test for allergies, providers can perform “a skin prick test” on a patient or
send the patient to a lab for “an allergy blood test.” Id., PageID 2671. The first test requires a
“technician” to prick the patient’s skin with allergens and measure the reactions. Id., PageID
2674. Doctors then interpret the results to decide whether a patient tested positive. Id. To make
this decision, they may also rely on a “physical examination” and the “patient’s clinical history.”
Id.
Many people use over-the-counter or prescription drugs to treat their allergies. Id.,
PageID 2673. But these drugs simply “mask” the symptoms and do not remedy the “underlying
cause” (at least for seasonal allergies). Id. Only one treatment—immunotherapy—can “cure”

-- 3 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 4
these allergies. Id., PageID 2671. Immunotherapy “introduc[es] allergens incrementally into the
patient’s system to desensitize the patient to [those] allergens.” Id.
Doctors can prescribe immunotherapy only if testing has confirmed a patient’s allergy.
Id., PageID 2674. Before doing so, they must consider immunotherapy’s risks and benefits
based on each patient’s unique needs. Id. When patients choose the therapy, technicians will
combine and dilute FDA-approved vials of antigens into proper doses for them. Id., PageID
2674–75. Doctors must supervise these technicians. Id. They or the technicians will administer
the immunotherapy through “subcutaneous” or “allergy” shots. Id., PageID 2675. Some patients
may receive the shots “2 to 3 times per week for several years” in a doctor’s office. Id., PageID
2676. Because patients must make frequent trips to a doctor’s office, they typically want
treatment “close to their homes or workplaces.” Id. And “a majority of physicians” permit
patients to self-administer the shots at home “in appropriate cases.” Id., PageID 2675.
Suppliers. Doctors who specialize in this area—called “allergists”—provide the main
supply of allergy testing and immunotherapy in Tennessee. Id., PageID 2669. To become an
allergist, a doctor must “complete[] a fellowship” with the American Board of Allergy and
Immunology. Id. And one corporation—the Allergy, Asthma and Sinus Center, P.C. or “the
Center” for short—dominates the Tennessee market. Id., PageID 2668–70. Its allergists conduct
about “70% of the allergy testing and immunotherapy services” across the State. Id., PageID
2670.
No law or regulation bars primary-care physicians from offering allergy testing or
immunotherapy. Id., PageID 2669–70. But these doctors historically have faced high barriers to
entry. Id., PageID 2669–71. To enter the market, doctors must hire technicians who know how
to conduct the skin-prick tests and prepare the allergens. Id. And they must obtain “expensive
equipment and products,” such as “testing devices” and “antigens and diluents[.]” Id. So rather
than perform these services, primary-care physicians have typically referred patients to allergists.
Id., PageID 2671–72. Many Tennesseans, though, live far from the closest allergist. The
restricted supply has allegedly caused many “patient consumers” to forgo treatment. Id., PageID

-- 4 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 5
2665. And it has caused the demand for services to “greatly exceed[]” the supply. Id., PageID
2668.
That is where United Allergy comes in. After recognizing the unmet demand, United
Allergy began to contract with primary-care physicians to help them offer allergy testing and
immunotherapy. Id., PageID 2670–71. United Allergy and its partnering physicians perform
different roles. United Allergy hires the technicians to “perform allergy testing and mix antigens
under the” physician’s supervision. Agreement, R.275-1, PageID 10151. It also provides “all
supplies and equipment necessary” for testing and immunotherapy. Id. The physicians, by
comparison, must “make all medical decisions[.]” Id., PageID 10152. They interpret the test
results and determine whether to prescribe immunotherapy. Id.; Compl., R.103, PageID 2671.
Since its 2013 entry into the Tennessee market, United Allergy has helped more than 80 primary-
care doctors provide allergy testing and immunotherapy. Compl., R.103, PageID 2671, 2677.
Many of these physicians practice in “rural areas” where the “nearest board-certified allergist is
many miles away.” Id., PageID 2671. And United Allergy technicians commonly teach patients
how to take the shots at home, so they can avoid regular trips to a doctor’s office. Id., PageID
2680, 2698–99.
Payors. Third-party payors (including private and government insurers) pay for all or
part of about “98%” of the allergy care. Id., PageID 2672. Tennessee’s Medicaid program
(“TennCare”) is one such payor. Id., PageID 2678. It contracts with three managed-care
organizations to insure eligible patients: Amerigroup Tennessee, Inc., BlueCare (a subsidiary of
Blue Cross Blue Shield of Tennessee), and United Healthcare. Id., PageID 2666–67, 2678.
The contracts between Tennessee and these three organizations run on for hundreds of
pages. Agreement, R.275-1, PageID 10161–68. They require Amerigroup (along with the other
two insurers) “to reimburse primary care physicians for” eligible claims involving allergy testing
and immunotherapy. Compl., R.103, PageID 2678. Physicians must bill Amerigroup under
general billing (or “CPT”) codes. Id., PageID 2673. For example, they use “CPT Code 95165”
to bill for services in administering immunotherapy to a patient. Id., PageID 2675.

-- 5 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 6
United Allergy, by contrast, does not contract with third-party payors for its technicians’
services or for the materials that it supplies to them. Rather, United Allergy receives fixed “fees”
from physicians for its goods and services. Agreement, R.275-1, PageID 10152. United
Allergy’s standard agreement with physicians states that its final fee for a service depends on the
“then current reimbursement schedule” of the third-party payor from whom physicians will seek
payment (such as Amerigroup). Id. The agreement adds that United Allergy’s services are
“incident to” a physician’s services for purposes of “federal and state billing guidelines” and that
the physicians have the duty to ensure that they can bill for all services. Id., PageID 10151.
B
United Allergy’s entry into the Tennessee market in 2013 caught the attention of
suppliers and payors of allergy-care services. The primary-care physicians who contracted with
United Allergy had been referring their allergy patients to the Center. Compl., R.103, PageID
2672, 2678. Yet these physicians now “became competitors” to the Center’s allergists. Id.,
PageID 2678. And as more doctors treated patients, third-party payors like Amerigroup spent
more reimbursing for care. Id., PageID 2672. TennCare pays Amerigroup on a “per member per
month” schedule set annually based on the prior year’s usage patterns. Id., PageID 2687. So the
sharp increase in supply allegedly harmed Amerigroup’s bottom-line more than TennCare’s. Id.
According to the complaint, Amerigroup and the Center responded by conspiring to drive
United Allergy and its partnering physicians from Tennessee. Id., PageID 2678–79. The Center
spearheaded these efforts through its management company (Physicians’ Medical Enterprises)
and that company’s business-development director (Ned DeLozier). Id., PageID 2667–68, 78–
83.
In April 2014, DeLozier learned of United Allergy’s threat to the Center. Id., PageID
2679. He tried to lobby public officials to bar United Allergy’s model and to discourage
primary-care physicians from contracting with it. Id., PageID 2679–80. When these efforts fell
short in 2016, DeLozier turned to Amerigroup and other third-party payors. Id., PageID 2680–
82. He allegedly encouraged these payors to conduct costly audits of United Allergy’s
partnering physicians. Id.

-- 6 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 7
Amerigroup estimated that it “stood to recover” around $6 million if it “flushed [United
Allergy] out of Tennessee[.]” Id., PageID 2690. Over the years, it allegedly searched for
reasons to deny payment to physicians who contracted with United Allergy and submitted claims
under the allergy-care billing codes. Id., PageID 2684. Amerigroup hypothesized that these
physicians might have engaged in “fraudulent billing” because the technicians performed
without supervision. Id., PageID 2687. It also hypothesized that these physicians had been
providing “medically unnecessary” care. Id., PageID 2688. And it hypothesized that the
physicians’ contracts with TennCare barred them from subcontracting work to United Allergy.
Id., PageID 2697–98.
From 2016 through 2019, the complaint adds, Amerigroup and DeLozier repeatedly
communicated with Amerigroup’s competing payors, including the other two managed-care
organizations, to convince them to investigate and stop paying United Allergy’s partnering
physicians. Id., PageID 2684–703. These conversations led all payors to ramp up their audits of
these physicians, to send them “recoupment” letters for paid bills, and to bar them from billing
for immunotherapy administered by patients at home. Id., PageID 2697–2700. The insurers also
agreed to “fixed prices” by reimbursing for a much smaller number of immunotherapy “doses”
than they had previously allowed. Id., PageID 2701.
The complaint says that the harassing efforts succeeded. Many primary-care physicians
stopped offering allergy-care services because Amerigroup and other insurers would not
reimburse them for these services and because they feared getting kicked out of TennCare. Id.,
PageID 2703–04. And United Allergy lost “profits” because these physicians refused to pay its
fees and later terminated their contracts with the company. Id., PageID 2704. The reduction in
output also left many patients without access to allergy care (especially in rural areas). Id.,
PageID 2704–05.
C
United Allergy sued Amerigroup, two Blue Cross entities, the Center, Physicians’
Medical Enterprises, and DeLozier. Id., PageID 2666–68. We will refer to the last three
(related) defendants as the “Center.” And United Allergy has since settled with the Blue Cross

-- 7 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 8
entities. The complaint asserted two federal antitrust claims and three state tort claims. As for
the federal claims, it alleged that the defendants violated § 1 of the Sherman Act by conspiring to
eliminate United Allergy and primary-care physicians from the allergy-care markets. Id.,
PageID 2705–08. It next alleged that the Center violated § 2 of the Sherman Act by
monopolizing these markets and that the others conspired to permit its monopoly. Id., PageID
2708–11. As for the state claims, the complaint alleged that the defendants tortiously interfered
with United Allergy’s contracts with physicians. Id., PageID 2711–15. It alleged that they also
tortiously interfered with United Allergy’s prospective relationships with physicians. Id.,
PageID 2714–15. And it alleged that they entered a civil conspiracy. Id., PageID 2715.
This litigation progressed in two stages. The defendants first moved to dismiss United
Allergy’s complaint. The district court dismissed the federal antitrust claims on the ground that
United Allergy lacked “standing” to sue under the antitrust laws. See United Biologics, LLC v.
Amerigroup Tenn., Inc., 2022 WL 22897162, at *4–9 (E.D. Tenn. Jan. 27, 2022). But the court
permitted the state-law claims to proceed. See id. at *9–11. After discovery, the defendants
moved for summary judgment on those claims. The district court then granted that motion. See
United Biologics, LLC v. Amerigroup Tenn., Inc., 2024 WL 770640, at *1 (E.D. Tenn. Jan. 18,
2024).
United Allergy appealed. It now challenges the dismissal of its antitrust claims and the
grant of summary judgment on its tort claims. We review both decisions de novo. See Aldridge
v. Regions Bank, 144 F.4th 828, 836 (6th Cir. 2025).
II. Federal Antitrust Claims
The Sherman Act contains two main prohibitions. Section 1 makes it illegal for
businesses to enter a “contract,” “combination,” or “conspiracy” “in restraint of trade or
commerce among the several States[.]” 15 U.S.C. § 1. And § 2 makes it illegal for businesses to
“monopolize, or attempt to monopolize, or combine or conspire with any other person or
persons, to monopolize any part of the trade or commerce among the several States[.]” Id. § 2.
We may assume that United Allergy has alleged violations of these sections. But this case is not
about the merits. It is about the remedies. And like the district court, we conclude that United

-- 8 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 9
Allergy has alleged only indirect injuries that flow out of the harms the defendants inflicted on
physicians. Unlike the district court, though, we characterize this defect as a lack of causation
rather than “standing.”
A. Antitrust “Standing”
The Sherman Act’s private right of action states: “[A]ny person who shall be injured in
his business or property by reason of anything forbidden in the antitrust laws may sue
therefor . . . , and shall recover threefold the damages by him sustained, and the cost of suit,
including a reasonable attorney’s fee.” 15 U.S.C. § 15(a). On its face, this text could be read to
permit any actor to sue for any harm that an antitrust violation causes. See Associated Gen.
Contractors v. Cal. State Council, 459 U.S. 519, 529 (1983). That view, though, would subject
defendants to unlimited liability because “antitrust violation[s]” often “cause ripples of harm”
throughout the economy. Blue Shield of Va. v. McCready, 457 U.S. 465, 476–77 (1982).
Consider the harms from a classic manufacturers’ cartel that raises prices and reduces
output. The cartel will harm retailers by requiring them to pay higher wholesale prices. Cf. Ill.
Brick Co. v. Illinois, 431 U.S. 720, 726–27 (1977). It will harm end consumers too if the
retailers pass on some of the cartel’s overcharge to them in the form of higher retail prices. Cf.
id. at 727. The reduced output might also harm the government by lowering its tax base. Cf.
Hawaii v. Standard Oil Co. of Cal., 405 U.S. 251, 255 (1972). Further, some retailers might not
survive under the higher prices. So the cartel will have injured the shareholders of these
bankrupt retailers. Cf. Stein v. United Artists Corp., 691 F.2d 885, 894–97 (9th Cir. 1982)
(Kennedy, J.); Loeb v. Eastman Kodak Co., 183 F. 704, 709 (3d Cir. 1910). The cartel will have
injured the bankrupt retailers’ other suppliers as well if those suppliers lose sales that they would
have made to the retailers. Cf. Static Control Components, Inc. v. Lexmark Int’l, Inc., 697 F.3d
387, 406 (6th Cir. 2012), aff’d on other grounds by 572 U.S. 118 (2014). The retailers’ creditors
(say, landlords) also might not get paid what the retailers owe (say, rent). Cf. Apple, 587 U.S. at
291 (Gorsuch, J., dissenting). And their employees might lose their jobs. Cf. Associated Gen.
Contractors, 459 U.S. at 541 n.46. In short, the list of harmed parties could go on and on.

-- 9 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 10
May all these parties seek treble damages from the cartel? No, the Supreme Court has
not read § 15(a) that way. In Associated General Contractors, it instead held that the law
permits suit only by those who have what some have dubbed “antitrust standing.” Id. at 535
n.31. In that case, construction contractors and their trade association sought to harm unions by
“coerc[ing]” customers (landowners who needed construction work) and contractors (the
defendants and their competitors) to shift business “to nonunion firms.” Id. at 527–28. Yet the
Court refused to allow the unions to sue. Id. at 536–46. It conceded that they alleged some facts
that supported the suit: that the conspiracy had caused their harm and that the defendants had
“intended” it. Id. at 537. But these allegations fell short. Among other reasons, the unions did
not participate as competitors or consumers in the construction market. Id. at 539. Rather, they
sought better pay for their members through labor cooperation (not competition). Id. at 539–40.
The unions thus did not rely on a “type” of harm (reduced competition) that “the antitrust statute
was intended to forestall.” Id. Next, the unions suffered “indirect” and “speculative” injuries
that flowed out of the harms to the customers and contractors. Id. at 540–42. So their suit would
create a “risk of duplicate recoveries” and require a “complex apportionment of damages”
among victims. Id. at 544.
Soon after Associated General Contractors, we identified five “factors” to decide
whether a plaintiff has antitrust standing. Southaven Land Co. v. Malone & Hyde, Inc., 715 F.2d
1079, 1085 (6th Cir. 1983) (citation omitted). First: Did the antitrust violation cause the
plaintiff’s injury and did the defendant intend it? See id. Second: Was the plaintiff’s “alleged
injury” the type that the antitrust laws seek to prevent? Id. Third: Was the injury direct or
indirect and were the damages concrete or speculative? See id. Fourth: Did the suit create a risk
of “duplicative recovery” by multiple victims or require a “complex apportionment of damages”
among those victims? Id. And fifth: Do “more direct victims” who could sue exist? Id.
At times, we have said that courts should engage in an ad hoc “balancing” of these
factors (and that we will treat no factor as “conclusive”). Peck v. Gen. Motors Corp., 894 F.2d
844, 846 (6th Cir. 1990) (per curiam); see Static Control, 697 F.3d at 402; Indeck Energy Servs.,
Inc. v. Consumers Energy Co., 250 F.3d 972, 976 (6th Cir. 2000); Province v. Cleveland Press
Pub. Co., 787 F.2d 1047, 1050–51 (6th Cir. 1986). Yet what happens when the factors point in

-- 10 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 11
different directions? Should we add them up and decide where the majority lands? May we find
one factor “really” important in a case? If so, when? Here, as elsewhere, amorphous balancing
tests can produce “unpredictable and at times arbitrary results.” Lexmark, 572 U.S. at 136.
In practice, then, we have avoided this balancing. Most notably, we have held that
plaintiffs must prove an “antitrust injury” in all cases. NicSand, Inc. v. 3M Co., 507 F.3d 442,
450 (6th Cir. 2007) (en banc) (citing Cargill, Inc. v. Monfort of Colo., Inc., 479 U.S. 104, 110 n.5
(1986)). Plaintiffs thus must always satisfy our second factor (which asks about the “nature” of
their injury). See Southaven, 715 F.2d at 1085–86. And we regularly reject suits for the lack of
an antitrust injury alone. See NicSand, 507 F.3d at 450–59; Tennessean Truckstop, Inc. v. NTS,
Inc., 875 F.2d 86, 88–91 (6th Cir. 1989); Axis, S.p.A. v. Micafil, Inc., 870 F.2d 1105, 1110–11
(6th Cir. 1989).
Next, the other four factors go to the same question: has the plaintiff shown that the
antitrust violation was both a cause in fact and a “proximate cause” of the harm? Apple, 587
U.S. at 279. In addition to the factor that expressly lists causation, two others consider the
“directness” of the injury and whether “more direct victims” could sue. Southaven, 715 F.2d at
1085. And the Supreme Court has since made clear that these directness questions form part of
the proximate-cause calculus. See Holmes v. Secs. Inv. Prot. Corp., 503 U.S. 258, 268–69
(1992).
The Supreme Court’s Lexmark decision confirms this logic. There, the Court addressed a
similar question: who may sue under the Lanham Act, 15 U.S.C. § 1125(a)? See 572 U.S. at
120. The Court answered that question by incorporating two “background principles” into the
Act: that a plaintiff must fall within a statute’s “zone of interests” and that the defendant must
have “proximately caused” the injury. Id. at 129–34. In the process, the Court clarified that
“standing” is the wrong label for this who-may-sue question because the question raises an
ordinary problem “of statutory interpretation” about the meaning of § 1125(a)’s text. See id. at
128. And the Court rejected an “open-ended balancing” test that was nearly identical to the one
that we and other circuit courts have sometimes proposed in this antitrust context. Id. at 135–36.

-- 11 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 12
Extended to the Sherman Act, Lexmark confirms that antitrust courts should not
abstractly balance various factors against each other. Rather, they should ask whether plaintiffs
have alleged an “antitrust injury” and “proximate causation.” We thus turn to those two
elements.
B. Antitrust Injury
1. What Types of Harms Count As “Antitrust Injuries”?
The Supreme Court presumes that Congress enacts legislation with knowledge of the
presumption that only plaintiffs who “fall within the zone of interests protected by” a law may
invoke its protections. Id. at 129 (citation omitted). In the antitrust context, this interpretive
principle has produced the “antitrust injury” requirement. Brunswick Corp. v. Pueblo Bowl-O-
Mat, Inc., 429 U.S. 477, 489 (1977). Section 15(a) allows plaintiffs to recover damages only if
they suffered harm “by reason of anything forbidden in the antitrust laws[.]” 15 U.S.C. § 15(a).
The Supreme Court has interpreted that phrase to require proof that a plaintiff’s harm grew out of
the underlying “rationale” for why the antitrust laws made the challenged conduct illegal. Atl.
Richfield Co. v. USA Petroleum Co., 495 U.S. 328, 342 (1990). Put differently, plaintiffs may
recover damages only if they show that they suffered a “type” of harm that Congress designed
the antitrust laws to prevent. Brunswick, 429 U.S. at 489 (citation omitted).
Courts thus must explore the purposes of §§ 1 and 2 of the Sherman Act. Those laws
represent a “consumer welfare prescription” from Congress. Reiter v. Sonotone Corp., 442 U.S.
330, 343 (1979) (quoting Robert H. Bork, The Antitrust Paradox 66 (1978)). When suppliers
enter cartels or undertake monopolizing acts, their conduct has a similar “anticompetitive effect”:
it increases prices and reduces output as compared to the price and output levels in competitive
markets. Brunswick, 429 U.S. at 489; see Ball Mem’l Hosp., Inc. v. Mut. Hosp. Ins., Inc., 784
F.2d 1325, 1334 (7th Cir. 1986). This effect harms two sets of consumers. It harms actual
consumers who still buy at the higher price because they must pay the “illegal overcharge” (the
difference between the higher cartel or monopoly price and the lower competitive price). Ill.
Brick, 431 U.S. at 724. It also harms potential consumers who now refuse to buy at the higher
price (hence why these violations reduce output). See Howard Hess Dental Labs. Inc. v.

-- 12 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 13
Dentsply Int’l, Inc., 424 F.3d 363, 374 (3d Cir. 2005). And while these “would-be buyers” who
forgo purchases lack the right to sue for other reasons, actual purchasers represent the “preferred
plaintiffs” who suffer the core antitrust injury. IIA Phillip E. Areeda & Herbert Hovenkamp,
Antitrust Law § 345a, at 197 & n.2 (5th ed. 2021); Reiter, 442 U.S. at 343.
That said, this case requires us to add a wrinkle to this usual analysis. Typically, a group
of sellers or one monopolistic seller engages in the acts prohibited by §§ 1 and 2. But a group of
buyers or a monopsony buyer might also violate these sections. See Mandeville Island Farms v.
Am. Crystal Sugar Co., 334 U.S. 219, 235–36 (1948); XII Phillip Areeda & Herbert Hovenkamp,
Antitrust Law § 2012, at 140 (4th ed. 2019). A buyers’ cartel has “symmetrical” anticompetitive
effects to a sellers’ cartel: the cartel lowers (rather than raises) prices and reduces output below
the competitive level. Vogel v. Am. Soc’y of Appraisers, 744 F.2d 598, 601–02 (7th Cir. 1984).
In other words, a buyers’ cartel charges “monopsony prices” (the prices that a single buyer
would demand) in the way that a sellers’ cartel charges “monopoly prices” (the prices that a
single seller would charge). Id.; see Omnicare, Inc. v. UnitedHealth Grp., Inc., 629 F.3d 697,
705 (7th Cir. 2011). The suppliers who sell to a buyers’ cartel thus qualify as preferred plaintiffs
who suffer a core antitrust injury too. See IIA Areeda & Hovenkamp, Antitrust Law § 350b, at
298–99.
Who else might sue? We have held that “competitors” harmed by a defendant’s antitrust
violations also may suffer the right kind of injury. Static Control, 697 F.3d at 404. Yet courts
must evaluate a competitor’s suit more cautiously. The antitrust laws protect “competition, not
competitors.” Brunswick, 429 U.S. at 488 (citation omitted). And an antitrust violator’s
competitors often have “divergent rather than congruent interests” to consumers. Ball Mem’l
Hosp., 784 F.2d at 1334; see Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574,
583 (1986). So a competitor’s lost profits may not be “a close approximation of the [antitrust]
injury caused by” a cartel’s or monopolist’s “overcharges.” Frank H. Easterbrook, Treble
What?, 55 Antitrust L.J. 95, 96 (1986). Suppose, for example, a large company violated the
antitrust laws by merging with near-bankrupt bowling alleys and saving them from closure. See
Brunswick, 429 U.S. at 480–81. Even if a competitor to these bowling alleys proved this
antitrust violation, it could not recover the profits it would have obtained if the illegal merger had

-- 13 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 14
not occurred and the bowling alleys had closed. See id. at 487–88. After all, the competitor’s
lost profits in that scenario would have arisen from the increased competition that resulted from
the otherwise illegal merger (which barred the competitor from harming consumers by charging
higher prices). See id.
To prove an antitrust injury, then, competitors must show that their “loss stems from a
competition-reducing aspect or effect of the defendant’s behavior.” Atl. Richfield, 495 U.S. at
344. Perhaps rivals who had formed an illegal cartel teamed up to eliminate a competitor who
was undercutting the cartel prices. See Hammes v. AAMCO Transmissions, Inc., 33 F.3d 774,
782–83 (7th Cir. 1994). Or perhaps competitors who must cooperate in an industry (such as real-
estate agents on both sides of a home sale) tried to drive out a rival by refusing to deal with the
rival in home sales. See Re/Max Int’l, Inc. v. Realty One, Inc., 173 F.3d 995, 1014–15 (6th Cir.
1999); see also W. Penn Allegheny Health Sys., Inc. v. UPMC, 627 F.3d 85, 103–05 (3d Cir.
2010).
What about other businesses less connected to the market? The Supreme Court has noted
that a plaintiff is less likely to have incurred an antitrust injury if it is neither a “consumer nor a
competitor in the market” that the defendants restrained. Associated Gen. Contractors, 459 U.S.
at 539; see In re Aluminum Warehousing Antitrust Litig., 833 F.3d 151, 158 (2d Cir. 2016).
Courts thus have found that third parties who helped a competitor (such as suppliers, employees,
or advertisers) did not suffer an antitrust injury from a defendant’s anticompetitive conduct—at
least not when the defendant “directed” that conduct at the competitor (rather than the third
parties). IIA Areeda & Hovenkamp, Antitrust Law § 350d, at 305–06; Static Control, 697 F.3d
at 404; Barton & Pittinos, Inc. v. SmithKline Beecham Corp., 118 F.3d 178, 182–83 (3d Cir.
1997) (Alito, J.); Serfecz v. Jewel Food Stores, 67 F.3d 591, 596–98 (7th Cir. 1995); SAS of P.R.,
Inc. v. P.R. Tel. Co., 48 F.3d 39, 44 (1st Cir. 1995). When third-party harm is mere “collateral
damage” to (or “a tangential byproduct of”) the anticompetitive conduct, the harm does not count
as an antitrust injury. Aluminum Warehousing, 833 F.3d at 163; Static Control, 697 F.3d at 404.

-- 14 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 15
2. Did United Allergy Allege An Adequate Antitrust Injury?
The district court held that United Allergy failed to allege an antitrust injury under this
law. See United Biologics, 2022 WL 22897162, at *5–8. But we find this question difficult. On
the one hand, United Allergy appears to be neither a “consumer nor a competitor” in the market
affected by the anticompetitive conduct: the market for “allergy testing and immunotherapy” in
Tennessee. Associated Gen. Contractors, 459 U.S. at 539; Compl., R.103, PageID 2671.
Consider this market’s two sides. Who are on the buyer’s side? The patients who receive
treatment are the main “consumers” (as the complaint calls them). Compl., R.103, PageID 2665.
And the insurers—including Amerigroup and the other managed-care organizations—sit on the
buyer’s side because they act as “purchasing agents” for these consumers. Ball Mem’l Hosp.,
784 F.2d at 1334; see Brillhart v. Mut. Med. Ins., Inc., 768 F.2d 196, 199 (7th Cir. 1985); Kartell
v. Blue Shield of Mass., Inc., 749 F.2d 922, 924 (1st Cir. 1984) (Breyer, J.). Who are on the
seller’s side? The doctors—both the Center’s “allergists” and the primary-care physicians who
want to compete with them—are the primary suppliers. Compl., R.103, PageID 2669–70. These
doctors must perform the allergy testing and immunotherapy services and supervise the
technicians who help them. Id., PageID 2668–70, 2674–75. And only they may bill insurers for
these services. Id., PageID 2678.
Where do these facts leave United Allergy? In many ways, it resembles a “supplier” to
the primary-care physicians and operates in a distinct market vertically upstream of the affected
one. Static Control, 697 F.3d at 404, 406. United Allergy provides physicians with the materials
and personnel (equipment, products, and technicians) they need to compete with the Center’s
allergists. Compl., R.103, PageID 2671. In fact, the complaint refers to primary-care physicians
themselves as United Allergy’s “customers” who buy its goods and services for a “fee” in this
upstream market. Id., PageID 2665, 2671, 2697. And United Allergy could not “sell or
distribute” its goods or services directly to patients in the downstream market because only
doctors may offer allergy testing and immunotherapy to patients. Barton & Pittinos, 118 F.3d at
182. The Center, by comparison, allegedly integrated upstream by employing its own
technicians and supplying its own equipment. Compl., R.103, PageID 2672, 2677. These
market dynamics might suggest that United Allergy did not suffer an antitrust injury because a

-- 15 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 16
“supplier does not suffer an antitrust injury when competition is reduced in the downstream
market in which it sells goods or services.” W. Penn Allegheny Health Sys., 627 F.3d at 102; see
Static Control, 697 F.3d at 406.
On the other hand, a preeminent antitrust treatise explains that when a plaintiff sells to a
third party and the two businesses together compete with an integrated defendant, both the
plaintiff and the third party are the defendant’s “competitors” in “every relevant economic
sense.” IIA Areeda & Hovenkamp, Antitrust Law § 348f, at 285. The complaint also suggests
that United Allergy did not simply suffer “collateral damage” from anticompetitive conduct
directed at primary-care physicians. Aluminum Warehousing, 833 F.3d at 163. It suggests that
United Allergy was also a “direct target” of the conduct. Compl., R.103, PageID 2666.
Lastly, the complaint might suggest that United Allergy suffered a “type” of harm that
the antitrust laws seek to prevent, Brunswick, 429 U.S. at 489 (citation omitted), because its
injuries arose “from a competition-reducing aspect” of the antitrust violations. Atl. Richfield,
495 U.S. at 344. United Allergy alleges an agreement between a seller (the Center) and several
buyers (Amerigroup, the other managed-care organizations, and Blue Cross) to “fix prices and
boycott competition at the primary care level.” Compl., R.103, PageID 2702. As for price
fixing, the complaint suggests that the insurers agreed “to fix prices for allergen immunotherapy
at a set amount of units” by “adopt[ing] similar reimbursement policies” for claims. Id., PageID
2686; cf. Mandeville, 334 U.S at 235–36. As for the boycott, the complaint suggests that
Amerigroup and the other insurers agreed “to harass all primary care providers” who offered
allergy testing and immunotherapy by auditing them, denying their claims, and seeking to recoup
payments. Compl., R.103, PageID 2680, 2697–700, 2703; cf. NYNEX Corp. v. Discon, Inc., 525
U.S. 128, 135–36 (1998). The reduced competition resulting from this horizontal cartel and
boycott would decrease prices and output below competitive levels. See Omnicare, 629 F.3d at
705. And although the suppliers to this alleged cartel—the physicians who receive less pay and
provide less services—might represent the preferred plaintiffs, see IIA Areeda & Hovenkamp,
Antitrust Law § 350b, at 298–99, the derivative injuries to United Allergy arose from the same
reduction in competition.

-- 16 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 17
Given these uncertainties about the antitrust-injury requirement, we opt to avoid this
issue. Even if United Allergy suffered such an injury, its suit still fails on proximate-causation
grounds.
C. Proximate Causation
1. When Do Antitrust Violations “Proximately Cause” A Plaintiff’s Injuries?
The Supreme Court also interprets private rights of action against the common-law rule
that plaintiffs may recover only if a defendant “proximately caused” their injuries. Lexmark, 572
U.S. at 132; Bank of Am. Corp. v. City of Miami, 581 U.S. 189, 201 (2017). And the Court has
incorporated this rule into § 15(a) because that law permits a plaintiff to sue only if the injury
occurred “by reason of” an antitrust violation. 15 U.S.C. § 15(a); Apple, 587 U.S. at 279.
Proximate causation imposes several limits on a defendant’s liability. See Holmes, 503
U.S. at 267. This doctrine sometimes bars a suit when the defendant could not reasonably
foresee the type of injury the plaintiff suffered. See Scheffer v. R.R. Co., 105 U.S. 249, 251–52
(1881). The doctrine also sometimes bars a suit if a “superseding cause” stood between the
defendant’s conduct and the plaintiff’s injury. Exxon Co., U.S.A. v. Sofec, Inc., 517 U.S. 830,
837 (1996) (citation omitted). And most relevant here, the doctrine sometimes bars a suit if a
“direct relation” does not exist “between the injury asserted and the injurious conduct alleged.”
Holmes, 503 U.S. at 268. When, for example, a defendant injures a third party, a plaintiff might
be unable to recover for derivative harms that flow out of that third party’s injuries. See id. at
268–69 (citing 1 J. Sutherland, Treatise on the Law of Damages 55–56 (1882)). As Justice
Holmes put it, “[t]he general tendency of the law, in regard to damages at least, is not to go
beyond the first step.” S. Pac. Co. v. Darnell-Taenzer Lumber Co., 245 U.S. 531, 533 (1918).
In the antitrust context, the Supreme Court has turned this general directness element into
a specific “rule” that applies when antitrust violators harm multiple parties along a vertical
“chain” of distribution. Apple, 587 U.S. at 279. The rule permits only “direct purchasers” (not
“indirect purchasers”) to sue a cartel or monopolist. Id. The Court adopted this rule in a pair of
cases: Hanover Shoe, Inc. v. United Shoe Machinery Corp., 392 U.S. 481 (1968), and Illinois
Brick. In Hanover Shoe, the Supreme Court identified the damages that arise to those who

-- 17 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 18
directly buy from a cartel or monopolist as the “amount of the overcharge” between the higher
cartel or monopoly price and the lower market price. 392 U.S. at 489. The Court calculated
damages in this way even though the plaintiff in that case was not an end consumer and had
likely passed on some of this overcharge to its own customers in the form of higher prices. See
id. at 492–93. The defendant thus sought to reduce its damages to the plaintiff by showing that
the plaintiff had avoided all or part of the overcharge’s harm. See id. at 491–92. The Court
rejected this “passing-on defense” to damages. Id. at 492–94. Why? It thought that the “task”
of proving the defense “would normally prove insurmountable.” Id. at 493. It added that
common-law rules would bar such a mitigation-of-damages theory. Id. at 490 & n.8 (discussing
S. Pac., 245 U.S. at 533–34).
Illinois Brick represents the “mirror image” of Hanover Shoe. William M. Landes &
Richard A. Posner, Should Indirect Purchasers Have Standing to Sue Under the Antitrust Laws?
An Economic Analysis of the Rule of Illinois Brick, 46 U. Chi. L. Rev. 602, 603 (1979). There, a
manufacturers’ cartel sold bricks to intermediaries, who resold the bricks (and passed on part of
the cartel’s overcharge) to end purchasers. Ill. Brick, 431 U.S. at 726. The “indirect” end
purchasers sued the manufacturers to recover the passed-on overcharge. Id. But the Supreme
Court rejected their suit. Just as a defendant cannot use a “pass on” theory in a “defensive” way
to reduce the damages owed to a direct purchaser, so too an indirect-purchaser plaintiff cannot
use the “pass-on” theory in an “offensive” way to seek damages. Id. at 729–30. The Court
adopted this view to eliminate the “serious risk of multiple liability for defendants.” Id. at 730.
And it adopted this view because the “difficulties in analyzing price and output decisions”
remained no matter who asserted the pass-on theory. Id. at 731–32; see Kansas v. UtiliCorp
United, Inc., 497 U.S. 199, 207–08 (1990).
Illinois Brick’s bright-line rule applies no matter which way the harm flows along a
vertical chain of distribution. Take a buyers’ cartel that reduces prices and output below
competitive levels. Sometimes the cartel’s “undercharge” (the difference between the higher
market price and the lower cartel price) will harm not just direct sellers from whom it buys (say,
wholesalers) but also indirect sellers from whom the direct sellers buy (say, manufacturers). And
Illinois Brick necessarily covers this reverse situation by permitting only the direct (not the

-- 18 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 19
indirect) sellers to sue the buyers’ cartel. See Zinser v. Cont. Grain Co., 660 F.2d 754, 760–61
(10th Cir. 1981); In re Beef Indus. Antitrust Litig., 600 F.2d 1148, 1158–59 (5th Cir. 1979); IIA
Areeda & Hovenkamp, Antitrust Law § 346g, at 228–29.
Nor can indirect purchasers (or sellers) avoid Illinois Brick by calculating their damages
using “lost profits” rather than an “overcharge” (or “undercharge”) valuation. A horizontal cartel
inflicts two harms on direct purchasers. They pay the overcharge for the products they continue
to buy, and they lose the additional profits they would have made for the products they stop
buying (and selling downstream to indirect purchasers) at the higher price. See Howard Hess,
424 F.3d at 373–74. Direct purchasers may seek to recover both the overcharge from the
completed sales and the lost profits from the “lost sales.” UtiliCorp, 497 U.S. at 212–13. And
Illinois Brick leaves no doubt that indirect purchasers may not recover the overcharge. See id. at
204. But may these indirect purchasers at least recover the lost profits from the reduced output
that flows down the distribution chain along with the overcharge? No, the Supreme Court’s
bright-line rule bars indirect purchasers from suing altogether—even if they seek these “lost
profits as opposed to overcharge damages.” Howard Hess, 424 F.3d at 375.
At the same time, courts must not overread Illinois Brick. Its bright-line rule does not
“bar multiple liability that is unrelated to passing an overcharge down a chain of distribution.”
Apple, 587 U.S. at 287. Antitrust violators sometimes directly contract with two parties—say, a
retailer who buys from suppliers and sells to consumers or a “two-sided platform” (like a credit-
card company) that facilitates an exchange between two sets of customers (card holders and
retailers). See id. at 282–85; Ohio v. Am. Express Co., 585 U.S. 529, 546 (2018). Take Apple,
which connects consumers who want to buy apps in the App Store on its iPhones with suppliers
who create these apps and put them in that store. See Apple, 587 U.S. at 276–77. If Apple has a
monopoly, it might force iPhone users to pay an overcharge for the apps, and it might force app
creators to sell at an undercharge to Apple. See id. at 286–88. In that scenario, both sides
directly purchased or sold to Apple, so both may sue for their discrete damages. See id. at 287–
88. Neither qualifies as an indirect purchaser or seller. See id.; see also McCready, 457 U.S. at
467–68.

-- 19 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 20
One last point. Even if the categorical rule from Illinois Brick does not apply, a plaintiff
might still not satisfy proximate causation under all the facts. See, e.g., In re Am. Express Anti-
Steering Rules Antitrust Litig., 19 F.4th 127, 138–43 (2d Cir. 2021). Many decisions, for
example, bar suits by “employees with merely derivative injuries” that arise from harms inflicted
on their employers. Associated Gen. Contractors, 459 U.S. at 541 n.46. This harm might not
fall within Illinois Brick, but it would not satisfy proximate causation all the same. See Adams v.
Pan Am. World Airways, Inc., 828 F.2d 24, 27–31 (D.C. Cir. 1987). Or take potential purchasers
who do not buy at a cartel price but who would have bought at the market price. These plaintiffs
also would not fall within Illinois Brick because they sit at the correct level of the distribution
chain. But the “existing rule” bars them from suing given the speculation required to decide
whether they would have bought. Frank H. Easterbrook, Detrebling Antitrust Damages, 28 J. L.
& Econ. 445, 463 (1985) (citing Montr. Trading Ltd. v. Amax Inc., 661 F.2d 864, 867–68 (10th
Cir. 1981)); IIA Areeda & Hovenkamp, Antitrust Law §§ 345a at 197 n.2, 391b1 at 399.
Likewise, would-be suppliers cannot simply claim they would have opened a business but for a
defendant’s anticompetitive conduct. See IIA Areeda & Hovenkamp, Antitrust Law § 349a, at
289. Rather, they must identify concrete steps they took to enter. See id. at 289–94; Sunbeam
Television Corp. v. Nielsen Media Rsch., Inc., 711 F.3d 1264, 1272–73 (11th Cir. 2013); In re
Dual-Deck Video Cassette Recorder Antitrust Litig., 11 F.3d 1460, 1464–66 (9th Cir. 1993);
Huron Valley Hosp., Inc. v. City of Pontiac, 666 F.2d 1029, 1033 (6th Cir. 1981). In sum, “[n]o
single formula captures the required proximity.” IIA Areeda & Hovenkamp, Antitrust Law
§ 339a, at 147.
2. Did The Alleged Antitrust Violations “Proximately Cause” United Allergy’s Injuries?
United Allergy has not plausibly alleged proximate causation under this framework.
Most notably, its complaint asserts the indirect harms that fall within the “bright-line rule” from
Illinois Brick. Apple, 587 U.S. at 279. As we have said, the complaint alleges that the Center
orchestrated a horizontal agreement among Amerigroup and its competing insurers to “fix prices
and boycott competition at the primary care level.” Compl., R.103, PageID 2702. Amerigroup
and the other insurers allegedly “fixed prices at the reimbursement level of 150 doses/units per
member per calendar year with a 3-month supply reimbursement restriction[.]” Id., PageID

-- 20 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 21
2701. So if physicians provided doses above these limits, the insurers paid zero. Id., PageID
2702. The insurers also allegedly conspired to deny the physicians’ claims on several pretextual
grounds. Id., PageID 2706–07. This horizontal agreement thus caused two basic harms: the
insurers denied claims for completed sales (in which physicians had already provided allergy-
care services to patients) and the insurers caused the market to suffer from lost sales (by
incentivizing the physicians to stop seeing patients because they knew they would not get paid).
But the complaint leaves no doubt that the physicians—not United Allergy—directly
suffered these harms. First consider the completed sales. The physicians directly sold to the
insurers and so directly suffered the undercharge from the horizontal agreement (the difference
between the market reimbursement rate and the insurers’ agreed rate of zero). Indeed, at least
one physician identified in the complaint (Dr. Christopher Sewell) sued to recover the full
amount of his “unreimbursed” claims (that is, the entire undercharge). Am. Compl., R.42, in
C.S. Sewell, M.D. P.C. v. Amerigroup Tenn., Inc., No. 2:17-cv-00062 (M.D. Tenn. Sept. 22,
2017); see Compl., R.103, PageID 2695. United Allergy, by contrast, was “two . . . steps
removed from the antitrust violator[s] in [the] distribution chain” because it sold to physicians
(its “customers”) for a fee. Apple, 587 U.S. at 280; Compl., R.103, PageID 2671, 2677. And
even if the physicians passed on some of the insurers’ undercharge to United Allergy (by
refusing to pay its fees if they did not get paid themselves), United Allergy could not sue as an
indirect seller. See Zinser, 660 F.2d at 760–61; Beef Indus., 600 F.2d at 1158–59. If both the
physicians could recover the full undercharge on these completed sales and United Allergy could
recover damages for the same sales, its suit would create a “risk of duplicative recoveries” for
the same injury. Ill. Brick, 431 U.S. at 730.
To be sure, United Allergy does not just seek damages for completed sales. It also seeks
far more damages for the lost sales that resulted from the vastly lower output at the fixed price of
zero. Its complaint alleges that the anticompetitive conduct reduced its output both because its
existing primary-care physicians suffered a “decrease in services” (they saw fewer patients) and
because prospective physicians refused to enter “new contracts” (they saw no patients). Compl.,
R.103, PageID 2704. We see two problems with this theory. For one, only direct purchasers or
sellers may recover for the “lost sales” (independent of any overcharge or undercharge) that flow

-- 21 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 22
out of an anticompetitive action’s reduction in output. UtiliCorp, 497 U.S. at 212–13. The
Supreme Court has read Illinois Brick to set forth a clear “rule of contractual privity,” and United
Allergy had no contractual relationship with the insurers. Apple, 587 U.S. at 289 (Gorsuch, J.,
dissenting).
For another thing, even apart from Illinois Brick’s rule, United Allergy seeks “highly
speculative” damages. Associated Gen. Contractors, 459 U.S. at 542. Take its request to
recover lost profits for the sales it might have made to prospective physicians who refused to
contract with it because of the insurers’ anticompetitive conduct. Just as “would-be buyers” may
not recover from a sellers’ cartel, “would-be” suppliers (like these prospective physicians)
generally may not sue unless they establish that they took concrete steps to enter the market. See
IIA Areeda & Hovenkamp, Antitrust Law § 345a, at 197 n.2; Dual-Deck, 11 F.3d at 1464–66.
And it would make no sense to allow a further-removed indirect seller (United Allergy) to sue if
these unidentified physicians cannot. United Allergy would have to prove that the physicians
refused to enter the market as “the result of the alleged” anticompetitive conduct. Holmes, 503
U.S. at 273. But the physicians could have refrained from doing so “for any number of reasons
unconnected” to that conduct. Anza v. Ideal Steel Supply Corp., 547 U.S. 451, 458 (2006).
United Allergy’s contrary arguments do not convince us otherwise. First, United Allergy
claims that Illinois Brick does not apply here because it alleges that the defendants participated in
a “boycott” rather than a price cartel. Appellant’s Supp. Br. 7. Set aside that the complaint
repeatedly alleges that the insurers “fixed prices” (or engaged in “price fixing”)—not just that
they engineered a boycott. Compl., R.103, PageID 2665, 2686, 2697, 2701–02, 2706–07, 2709–
10. Plaintiffs cannot avoid Illinois Brick through artful pleading. See Merican, Inc. v.
Caterpillar Tractor Co., 713 F.2d 958, 967 (3d Cir. 1983). That decision establishes a
proximate-causation rule tied to § 15(a)’s “by reason of” language—not a rule of substantive
liability tied to §§ 1 or 2. So we see no textually plausible path for holding that a party who is
“two or more steps removed from the antitrust violator in a distribution chain” may sue if the
party alleges something other than price fixing. Apple, 587 U.S. at 280. And whether the
defendants’ conduct is labeled a boycott, a cartel, or anything else, United Allergy’s harms are
“two . . . steps removed from the antitrust violator[s]” because its harms flow out of the injuries

-- 22 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 23
inflicted on its “customers” up the chain: the physicians. Id.; Compl., R.103, PageID 2665.
Indeed, the complaint alleges a “boycott” at the “primary care level”—meaning a boycott of the
“primary care physicians” (directly) and United Allergy (indirectly). Compl., R.103, PageID
2705–06 (emphasis added).
The cases on which United Allergy relies for this point do not support a different result.
See In re Brand Name Prescription Drugs Antitrust Litig., 123 F.3d 599, 606 (7th Cir. 1997); see
also Novell, Inc. v. Microsoft Corp., 505 F.3d 302, 311 n.17 (4th Cir. 2007); Mid-West Paper
Prods. Co. v. Cont’l Grp., Inc., 596 F.2d 573, 585 n.47 (3d Cir. 1979). In Brand Name
Prescription Drugs Antitrust Litigation, Judge Posner suggested in dicta that Illinois Brick
“would fall away” if the plaintiffs had alleged a “boycott” rather than price fixing. 123 F.3d at
606. But United Allergy ignores his reason why. Illinois Brick would not apply to a boycott
theory in that case because the plaintiffs could have alleged that the defendants refused “to enter
into direct contractual relations” with the defendants—so they would have suffered the boycott
harms directly (not through the boycott of other parties). Id. Judge Posner even conceded that
Illinois Brick might apply to a boycott allegation if the plaintiffs were still “seeking to recover
overcharges, for that would entail the very [pass-through] analysis that Illinois Brick bars.” Id.
As for Mid-West Paper Products, the Third Circuit has since clarified that it did not limit Illinois
Brick to cartel claims. Merican, 713 F.2d at 967. So Merican applied Illinois Brick to boycott
allegations. See id. at 966–68. Lastly, the Fourth Circuit in Novell found that the plaintiff was
the “most direct victim” of the anticompetitive conduct in that case and did not suffer its injury
indirectly through harms inflicted on others. 505 F.3d at 319. That case thus did not implicate
Illinois Brick.
Second, United Allergy argues that its request for “lost profits” (rather than for
undercharge damages) eliminates the concerns with “duplicative recovery” that drove Illinois
Brick and so eliminates the need for us to apply its rule here. Appellant’s Supp. Br. 8–10.
United Allergy’s premise is true: Illinois Brick expressed concern with the “risk of duplicative
recoveries” from allowing indirect purchasers to sue. 431 U.S. at 730. Recall that Hanover Shoe
held that a direct purchaser could recover the full overcharge from a monopolist even if the
purchaser passed on that overcharge to its consumers. See 392 U.S. at 489–94. To allow the

-- 23 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 24
indirect consumers to recover the passed-on overcharge, then, would force the defendant to pay
twice for the same harm. See Ill. Brick, 431 U.S. at 730–31. This duplicity risk might arise here
if, for example, physicians like Dr. Sewell could recover the full undercharge for denied claims
on completed sales (that is, the difference between the market price and the fixed lower price of
$0 that the insurers agreed to). Still, we agree that this duplicity concern would not arise if
courts limited both direct and indirect victims only to their lost profits. Here, for example, if the
primary-care physicians could seek only the lost profits from both completed and lost sales, their
damages would exclude their costs (which would include United Allergy’s set fees on these
sales). United Allergy and the physicians thus would have nonoverlapping damages under this
damages measure.
But United Allergy’s conclusion (that Illinois Brick should not apply) does not follow
from this premise. To the contrary, this logic would overrule Illinois Brick. As the Third Circuit
has explained, indirect purchasers and sellers could always recharacterize their damages as lost
profits rather than overcharges or undercharges for completed sales. See Howard Hess, 424 F.3d
at 376. But Illinois Brick categorically bars suits by indirect purchasers or sellers; it does not bar
them from only specific types of remedies. See id. at 375–76. This reading of Illinois Brick best
reconciles it with § 15(a)’s text. Under that text, a plaintiff may sue only for harms suffered “by
reason of” an antitrust violation. We do not see how one type of harm to an indirect party (the
lost profits for lost sales) could qualify as “by reason of” the violation while another type of
harm to that party (the undercharge or overcharge for completed sales) could not. See id. at 375–
76. Put another way, Illinois Brick adopts a plaintiff-specific rule, not a damages-specific rule.
Besides, Illinois Brick did not establish its rule just because of the risk of duplicative
damages. It also established its rule because “of the uncertainties and difficulties in analyzing
price and output decisions ‘in the real economic world rather than an economist’s hypothetical
model[.]’” Ill. Brick, 431 U.S. at 731–32 (citation omitted). And it established its rule because
of the administrative concerns with forcing judges and juries to make these calculations. See id.
at 732. These concerns remain even if an indirect seller labels its claim as one for “lost profits”
rather than an undercharge. See IIA Areeda & Hovenkamp, Antitrust Law § 346g, at 228.

-- 24 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 25
Lastly, Illinois Brick creates a “bright-line rule” that applies across the board—not a fact-
specific standard that courts may disregard when its rationales are absent. Apple, 587 U.S. at
279. So even when all agreed that a state-regulated utility passed on 100% of an energy cartel’s
overcharge to consumers, the Court still held that those consumers could not sue. See UtiliCorp.,
497 U.S. at 208–17. The Court thought it “unwarranted” to decide on the applicability of Illinois
Brick on a case-by-case basis. See id. at 217. And once we accept that Illinois Brick applies to
indirect sellers (not just purchasers), its “bright-line rule” covers this case. Apple, 587 U.S. at
279.
Third, United Allergy suggests that Illinois Brick should not apply because the complaint
describes United Allergy as the “intended target” of the anticompetitive conduct. Appellant’s
Br. 29. And it claims that proximate causation always exists for the intended victims of
intentional torts. But this “‘target’ theory of antitrust liability would nullify the doctrine of
Illinois Brick.” Motorola Mobility LLC v. AU Optronics Corp., 775 F.3d 816, 822 (7th Cir.
2015) (Posner, J.). A manufacturers’ cartel almost always targets the end consumers for higher
prices—that is, it almost “always knowingly causes injury to” these “indirect purchasers”—
because it will set its wholesale prices based on the anticipated higher retail prices that its price
fixing will cause downstream. See id. at 823. But indirect purchasers could not avoid Illinois
Brick by claiming that the cartel intended their downstream harms. See id. at 822. The same
logic should also apply in reverse to a buyers’ cartel: an indirect seller cannot avoid Illinois Brick
with the claim that the cartel intended to “driv[e]” the indirect seller “out of business” through its
anticompetitive conduct. IIA Areeda & Hovenkamp, Antitrust Law § 346g, at 228. As a treatise
has explained, “[s]o long as Illinois Brick stands, the courts cannot allow evasion of its policies
by artfully transforming a monopsony undercharge claim into a plan to destroy . . . upstream
producers” like United Allergy. Id.
Even apart from Illinois Brick, the Supreme Court’s cases contradict United Allergy’s
claim that the intended victims of antitrust violations always satisfy proximate cause. The
unions in Associated General Contractors, for example, alleged that the conspiring trade
association and contractors “intended to cause” them harm. 459 U.S. at 537. The lone dissent
thus agreed with United Allergy that the unions were analogous to the “victim of an intentional

-- 25 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 26
tort” and so could sue without any inquiry into proximate causation. Id. at 548 (Marshall, J.,
dissenting). But the Court rejected this conclusion, holding that this specific-intent allegation
was not a “panacea that will enable any complaint to withstand a motion to dismiss.” Id. at 537
(majority opinion). When discussing proximate causation in other contexts, the Court has
reached the same result. See Hemi Grp., LLC v. City of New York, 559 U.S. 1, 12 (2010). So a
competitor harmed by a defendant’s refusal to pay taxes could not sue even though the defendant
acted with the specific intent to gain an advantage over (and take sales from) the competitor. See
Anza, 547 U.S. at 455–58; Gen. Motors, LLC v. FCA US, LLC, 44 F.4th 548, 560–61 (6th. Cir.
2022).
This rule makes sense. Suppose that the primary-care physicians had hired technicians as
employees rather than obtain independent-contractor technicians from United Allergy. If the
employee technicians claimed that they lost their jobs because the defendants intentionally
targeted them with their anticompetitive conduct, could they sue over their lost wages? No,
because of the “speculative” nature of their damages and the risk of “unduly complex litigation”
in trying to figure out the harms passed on to these indirect employees. See Adams, 828 F.2d at
30–31. The rule should not be different simply because the physicians relied on independent
contractors rather than employees for the same technician services.
Fourth, United Allergy analogizes its claims to those in three cases that did not trigger
Illinois Brick. But none of these cases involved an indirect seller seeking to recover for harms
inflicted on a direct seller and passed down a distribution chain. Start with the Supreme Court’s
McCready decision. There, an insurer conspired with a psychiatric-services association to harm
psychologists by broadly covering psychiatry—but not psychology—services. See McCready,
457 U.S. at 468. A patient who opted to see a psychologist despite the lack of coverage paid for
the services out of pocket and sought to recoup this payment from the insurer and psychiatric-
services association. See id. at 468–69. The Court held that the patient could sue. See id. at
473–84. It reasoned that the patient did not seek money for injuries flowing “along a chain of
distribution” that arose “from a single transaction” up the chain. Id. at 475. To the contrary, the
insurer in McCready resembled the retailer in Apple: it acted as an “intermediary” between
medical providers on the one side and patients (and their employers) on the other. Apple, 587

-- 26 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 27
U.S. at 287. When an insurer acts anticompetitively, parties on both sides of the insurer (just like
upstream suppliers and downstream consumers on both sides of a retailer) can sue to recover
their distinct damages. See id. But McCready’s holding does not matter here because United
Allergy sits one step removed from the primary-care physicians on the same supply side of the
insurers. United Allergy thus would be analogous to a (fictional) medical supplier that sold
services to the psychologists in McCready to help them serve patients. But nothing in McCready
suggests that this type of indirect seller could sue in addition to the psychologists themselves (the
directly harmed sellers).
United Allergy fares no better with its reliance on Potters Medical Center v. City
Hospital Association, 800 F.2d 568 (6th Cir. 1986). There, the bigger hospital in a city refused
to grant staff privileges to doctors who held privileges at the city’s smaller hospital. See id. at
571. We concluded that the smaller hospital could sue the bigger one over this exclusive
dealing. See id. at 575–76. Yet Potters involved a suit between two competitors who sat at the
same level in the market. The hospitals directly contracted with physicians in the physician-
labor market, and the exclusive-dealing restraint reduced the supply of labor for the smaller
hospital. See id. at 575. We thus viewed that hospital as a “direct victim” of the restraint. Id. at
576. This case might resemble Potters if the Center had restrained the upstream market for
technician labor—say, by adopting an exclusive-dealing arrangement that barred its technicians
from working for competitors. But United Allergy makes no such claim. Rather, it says that the
Center convinced insurers to engage in price fixing and a boycott in the downstream market for
allergy testing and immunotherapy. The restraints in that market directly harmed the primary-
care physicians and indirectly harmed upstream actors with whom the physicians contracted,
such as United Allergy. So this case (unlike Potters) involves an upstream plaintiff indirectly
injured by a downstream restraint that affected “different levels of a distribution chain[.]” Apple,
587 U.S. at 287.
United Allergy’s citation to Crimpers Promotions, Inc. v. Home Box Office, Inc., 724
F.2d 290 (2d Cir. 1983) (Friendly, J.), fails for the same reason. That case concerned the market
for cable-television programs. See id. at 291. Producers had been selling these programs to the
two monopolist intermediaries (HBO and Showtime), which had been reselling them

-- 27 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 28
downstream to local cable-television operators. See id. The antitrust plaintiff—a competing
intermediary—sought to hold a tradeshow that would bring together program producers and
cable-television operators outside the HBO and Showtime bottleneck. See id. When HBO and
Showtime learned of this tradeshow, they discouraged program producers and cable-television
operators from attending. See id. The court held that Illinois Brick did not bar the plaintiff from
suing HBO and Showtime for the harms that they caused its tradeshow. See id. at 293–94. The
plaintiff competed with HBO and Showtime; it did not buy programming from them or sell it to
them. Its tradeshow harms thus differed from the monopsony undercharge and monopoly
overcharge that the program producers and cable-television operators paid. See id. at 293–94.
Crimpers would resemble this case if a competing insurer (at the intermediary level) sued
Amerigroup and the other insurers for hindering its efforts to enter the market and break up their
price fixing and boycott. This hypothetical insurer likely could sue because its injuries would
differ from those of the primary-care physicians and patients. But United Allergy resembles a
supplier to the program producers, one that seeks to recover for harms that those producers
passed along as a result of HBO’s and Showtime’s anticompetitive conduct. That type of suit
falls within Illinois Brick, not Crimpers.
Fifth, and finally, United Allergy falls back on policy arguments. See Appellant’s Supp.
Br. 13. It claims to be a better plaintiff than the primary-care physicians because it suffered a
single large injury while the physicians suffered smaller, dispersed injuries. And it says the
physicians may have a disincentive to enforce the antitrust laws because their livelihood depends
on obtaining reimbursement from the very insurance companies that they would have to sue.
Yet, as the complaint notes, these concerns have not prevented at least one other physician (Dr.
Sewell) from suing over the same conduct. Compl., R.103, PageID 2695. Nor is it obvious that
United Allergy’s “lost profits” (rather than undercharge damages) represent the proper antitrust
remedy because these sorts of profits “get lost primarily from hard competition or from the
elimination of monopoly”—not from anticompetitive conduct. Easterbrook, supra, 55 Antitrust
L.J. at 100; see Howard Hess, 424 F.3d at 375. All the same, we find the competing sets of
policy arguments beside the point. The arguments cannot overcome the legal problem with this
suit: United Allergy is “two . . . steps removed from” the insurers in the “distribution chain” for

-- 28 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 29
allergy testing and immunotherapy services. Apple, 587 U.S. at 279. It thus “may not sue”
under Illinois Brick. Id.
III. State Tort Claims
United Allergy also argues that the district court wrongly granted summary judgment to
the Center and Amerigroup on its three state-law claims. We will consider each claim in turn.
A. Tortious Interference with Existing Contracts
Tennessee common law and statutory law both prohibit defendants from intentionally
inducing a third party to breach its contract with a plaintiff. See Tenn. Code Ann. § 47-50-109;
Quality Auto Parts Co. v. Bluff City Buick Co., 876 S.W.2d 818, 822 (Tenn. 1994). Under either
law, this tort has the same seven elements. See Edwards v. Travelers Ins. of Hartford, 563 F.2d
105, 120 (6th Cir. 1977); Givens v. Mullikin ex rel. Est. of McElwaney, 75 S.W.3d 383, 405
(Tenn. 2002). The plaintiff must have entered a valid contract with a third party. See Givens, 75
S.W.3d at 405. The defendant must have known of this contract. See id. The defendant must
have intended to induce the third party to breach the contract. See id. When engaging in its
tortious actions, the defendant must have harbored “malice” toward the plaintiff. See id. The
third party must have breached the contract. See id. The defendant’s actions must have
proximately caused that breach. See id. And the breach must have injured the plaintiff. See id.
Here, United Allergy alleges that the Center and Amerigroup induced primary-care
physicians to breach their contracts with it. On appeal, the Center and Amerigroup do not
dispute most of the elements of this tortious-interference claim. They concede that United
Allergy formed valid contracts with primary-care physicians and that they knew of these
contracts. In the district court, the Center and Amerigroup did argue that United Allergy failed
to show that the physicians breached the contracts. But a United Allergy officer testified that 60
contracting clinics had “at some point in time” made at least one “late payment” to United
Allergy in violation of their contract’s payment terms. McMahon Decl., R.299-12, PageID
16951. The district court held that this testimony created a genuine dispute over the “breach”
element, and the Center and Amerigroup do not challenge this conclusion on appeal. See United
Biologics, 2024 WL 770640, at *12. Next, we find it debatable whether the Center and

-- 29 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 30
Amerigroup knew of the contractual provision requiring physicians to timely pay United
Allergy, and some caselaw suggests that defendants cannot intend “to induce” a breach of a
contractual “duty” that they do not know about. TSC Indus., Inc. v. Tomlin, 743 S.W.2d 169,
173 (Tenn. Ct. App. 1987). But we need not consider this issue. The Center and Amerigroup do
not dispute that enough evidence existed to suggest that they intended to cause the late-payment
breaches (and that the breaches harmed United Allergy).
These concessions leave the “malice” and “proximate causation” requirements. United
Allergy’s claims against the Center and Amerigroup collapse at one or the other of these
elements. The company has failed to present enough evidence that Amerigroup maliciously
caused any of the identified breaches or that the Center proximately caused them.
1. Amerigroup. To prove that Amerigroup tortiously interfered with United Allergy’s
contracts with the 60 physician clinics, United Allergy must show that Amerigroup acted with
“malice.” See Cambio Health Sols., LLC v. Reardon, 234 F. App’x 331, 336–37 (6th Cir. 2007).
Like the Restatement of Torts, Tennessee courts have held that “malice” does not require a
defendant to have “ill will” toward a plaintiff. Crye-Leike Realtors, Inc. v. WDM, Inc., 1998 WL
651623, at *6 (Tenn. Ct. App. Sept. 24, 1998); Riggs v. Royal Beauty Supply, Inc., 879 S.W.2d
848, 851 (Tenn. Ct. App. 1994); Restatement (Second) of Torts § 766 cmt. s (A.L.I. 1979).
Rather, these courts have concluded that a defendant need only commit a “wil[l]ful violation of a
known right”—a phrase that requires the defendant to have acted “without legal justification.”
Crye-Leike Realtors, 1998 WL 651623, at *6 (citation omitted); see Riggs, 879 S.W.2d at 851.
A pair of cases about noncompete agreements show both that a legally defensible
position cannot establish malice and that a legally indefensible position can. Compare HCTec
Partners, LLC v. Crawford, 676 S.W.3d 619, 642–43 (Tenn. Ct. App. 2022), with Riggs, 879
S.W.2d at 851–52. In Riggs, an employee plaintiff signed a noncompete agreement with the
defendant but switched jobs to work for a new employer. See 879 S.W.2d at 849. The defendant
sent a letter to this new employer disclosing the noncompete agreement, which caused the new
employer to fire the employee. See id. The employee claimed that the defendant had wrongly
induced the new employer to breach its contract with him because the defendant should have

-- 30 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 31
known that state courts would not enforce the noncompete agreement. See id. But the state
court held that the defendant had not acted maliciously because it “would have been justified in
litigating” the validity of the noncompete agreement even if a court would not have enforced it.
See id. at 851–52. In HCTec Partners, by contrast, a business plaintiff sued a competitor for
convincing an employee to quit and work for the competitor. See 676 S.W.3d at 625–26. This
time, the state court held that the plaintiff had established malice. See id. at 642. It reasoned that
the competitor had known of the noncompete agreement’s validity and convinced the employee
to violate the agreement anyway based on the mere hope that the plaintiff “would not bother to
sue” over it. Id. at 642–43.
Amerigroup looks more like the defendant in Riggs than the one in HCTec Partners. To
start, the insurer did not act with malice because it investigated the primary-care physicians (and
denied their claims) “to protect a third person toward whom [it stood] in a relation of
responsibility”: TennCare. Mefford v. City of Dupontonia, 354 S.W.2d 823, 827 (Tenn. Ct. App.
1961) (quoting William L. Prosser, Handbook of the Law of Torts 736–37 (2d ed. 1955)). As
one of three managed-care organizations that contract with TennCare to operate Tennessee’s
Medicaid program, Amerigroup has promised to protect public funds against fraud and waste.
So its contract with TennCare requires it to adopt “utilization control programs and procedures”
that “safeguard the Medicaid funds against unnecessary or inappropriate use of Medicaid
services and against improper payments.” Contract, R.275-3, PageID 10471; see 42 C.F.R.
§ 438.608(a). And Amerigroup must “cooperate” with state and federal agencies that investigate
fraud. Contract, R.275-3, PageID 10472. Amerigroup also must notify TennCare of “suspected
fraud cases” and generally undertake a “preliminary investigation” of the fraud. Id., PageID
10472–73.
Amerigroup’s actions against the physicians sprang from these duties. Indeed, TennCare
itself repeatedly raised concerns with allergy-care billing. Its concerns arose as early as 2015
before Ameriprise even knew of United Allergy’s existence. Mem., R.275-1, PageID 10144–50.
At that time, TennCare “recommend[ed]” “a benefit limitation for allergen immunotherapy” to
help its budget. Id., PageID 10144. This recommendation followed from an allergy-care
investigation showing (among other things) that physicians “billed” an “[e]xcessive number of

-- 31 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 32
units” and that “[t]he person/facility preparing the antigen . . . [was] not the provider/facility who
billed and received payment for the service.” Id., PageID 10145. The next year, the Tennessee
legislature limited immunotherapy billing to no more “than a three month supply at a time.”
Mem., R.275-5, PageID 10796. And TennCare ultimately asked its managed-care organizations
to “meet to discuss . . . a unified reimbursement policy concerning allergy immunotherapy.”
Email, R.275-10, PageID 11507. After these discussions, TennCare “decided to implement”
uniform billing for the immunotherapy that patients administered at home. Email, R.275-10,
PageID 11587.
By investigating physicians, Amerigroup simply responded to the concerns of its
principal: TennCare. It, for example, audited the allergy-care billings of Dr. Sewell (the
primary-care physician who sued) because of a referral from TennCare. Taylor Dep., R.275-10,
PageID 11581–82. And it learned of Sewell’s affiliation with United Allergy only through that
audit. Id.
Amerigroup also had “legal justification” to investigate (and deny the claims of) the
primary-care physicians who contracted with United Allergy. HCTec Partners, 676 S.W.3d at
642 (citation omitted). Amerigroup implements TennCare by contracting with physicians to
provide services to eligible patients. Contract, R.275-14, PageID 12136. Under these contracts,
physicians agree that they and their “employees shall perform all the services required hereunder
directly and not pursuant to any subcontract between [them] and any other person or entity[.]”
Id., PageID 12152. They also agree that Amerigroup could “deny payment” if the medical
“services” were not “provided in accordance with this Agreement.” Id., PageID 12148.
Interpreting these provisions, Amerigroup concluded that it could deny the physicians’ claims
because United Allergy’s contracts with them qualified as improper subcontracts. Email, R.299-
6, PageID 16043. One of TennCare’s own agents even flagged this subcontractor issue for
Amerigroup’s “investigation” of United Allergy “and other providers.” Email, R.275-15,
PageID 12350. Like the employer in Riggs, then, Amerigroup was “justified in litigating” the
issue, and it did not act with malice merely by asserting a reasonable legal position. 879 S.W.2d
at 852. The contrary rule

-- 32 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 33
would turn every disputed legal or contractual question into a potential tortious-interference
claim.
United Allergy’s responses do not change things. It first points to a 2018 email from an
Amerigroup employee that compiled allergy-care payment data after Amerigroup “opened all of
the cases on” United Allergy. Email, R.299-5, PageID 15972. This data showed a significant
drop in payments between 2015 and 2017. Id., PageID 15971–72. That said, the employee
explained that Amerigroup had not “completely flushed [United Allergy] out of Tennessee”
because it had investigated only the top billers and a lot of “little clinics” might still have
contracts with United Allergy. Id., PageID 15971. United Allergy suggests that this language
(about flushing out United Allergy) shows malice. Yet Amerigroup took the legal position that
the physicians’ contracts with Amerigroup barred them from using United Allergy to perform
allergy-care services without preapproval. So Amerigroup did not believe that United Allergy
possessed any “right” to contract with physicians. HCTec Partners, 676 S.W.3d at 642 (citation
omitted). And if it did not, Amerigroup had full authority to deny claims to physicians who
contracted with United Allergy.
United Allergy next cites workgroup notes suggesting that Amerigroup did not
subjectively believe that United Allergy’s relationship with physicians violated the subcontract
rule. One stray statement in these notes provides: “Not considered a subcontracted service.”
Notes, R.299-6, PageID 16037. This unexplained statement does not create a genuine issue of
material fact about Amerigroup’s beliefs. Indeed, the notes elsewhere state that “[p]rovider is in
contract violation” on the ground that “[s]ubcontracts must be pre-approved[.]” Id. And
overwhelming evidence otherwise shows that Amerigroup had concluded that United Allergy’s
contracts with physicians qualified as a “material breach” of the subcontractor provision in
Amerigroup’s own contracts with those physicians. Audit, R.299-1, PageID 15590.
United Allergy counters that Amerigroup still acted with malice because it unreasonably
held this belief. Its evidence? A 2017 letter from TennCare allegedly told Amerigroup that “the
subcontract issue had been resolved and that no enforcement action was intended against” United
Allergy. Appellant’s Br. 49. But United Allergy misrepresents this letter—which concerned

-- 33 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 34
Amerigroup’s decision to refer Dr. Sewell’s potential fraud to TennCare. Amerigroup’s contract
with TennCare did not permit it to seek to recoup funds from providers while they were “being
investigated” by TennCare. Contract, R.275-3, PageID 10471–72. In the letter, TennCare said it
was “returning the above case back to” Amerigroup, that Amerigroup should “proceed forward
with action as [it] deem[ed] necessary,” and that it should let TennCare know if it sought to
recoup funds. Letter, R.299-6, PageID 16042. So Amerigroup read the letter as allowing it “to
move forward” against Sewell. Email, R.299-6, PageID 16041. And no jury could read the
letter (as United Allergy does) to suggest that TennCare approved Sewell’s contract with United
Allergy.
United Allergy also points to a state-court decision that allegedly “rejected”
Amerigroup’s conclusion that Dr. Sewell had entered an improper subcontract with United
Allergy. Reply Br. 23. Not so. The state court found a dispute of fact that required a jury trial
on this question. Order, R.352-43, PageID 20886–87. If anything, then, this order proves
Amerigroup’s point. Even if it mistakenly interpreted the subcontract provision, the disputed
fact question shows Amerigroup was at least “justified in litigating” the issue. Riggs, 879
S.W.2d at 852. In sum, Amerigroup did not act with malice as a matter of law because it had a
“legal justification” for its conduct. Crye-Leike Realtors, 1998 WL 651623, at *6.
2. The Center. We need not consider the Center’s alleged “malice” because United
Allergy’s claim against it fails on causation grounds. To prove tortious interference, United
Allergy must show that actions attributable to the Center caused the 60 physician clinics to
breach their contracts. See Givens, 75 S.W.3d at 405. In common-law tort suits, the Tennessee
Supreme Court has required a plaintiff to prove that the defendant’s conduct “was both the
cause-in-fact and the legal cause” of the plaintiff’s injury. Cotten v. Wilson, 576 S.W.3d 626,
638 (Tenn. 2019); Hale v. Ostrow, 166 S.W.3d 713, 718 (Tenn. 2005). To satisfy the cause-in-
fact requirement, plaintiffs must prove but-for causation. See Cotten, 576 S.W.3d at 638; King v.
Andersen County, 419 S.W.3d 232, 246 (Tenn. 2013). That is, they must show that they would
not have suffered their injuries “but for” the defendant’s conduct. Jenkins v. Big City
Remodeling, 515 S.W.3d 843, 852 (Tenn. 2017). To satisfy the legal-cause requirement,
plaintiffs must establish proximate causation. See Cotten, 576 S.W.3d at 638. The Tennessee

-- 34 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 35
Supreme Court has interpreted “proximate causation” to include three primary requirements. See
id. The defendant’s conduct must have been a “substantial factor” in the plaintiff’s injury. Id.
(citation omitted). A decision to hold the defendant liable for this conduct must not conflict with
any “rule or policy” that would relieve the defendant of liability. Id. (citation omitted). And a
reasonable person must have been able to foresee that the plaintiff’s injury would arise from the
defendant’s actions. See id.
United Allergy cannot establish causation against the Center because any reasonable jury
would reach the same conclusion on this summary-judgment record: that the Center’s actions
were not “substantial factors” in bringing about the claimed contract breaches. Naifeh v. Valley
Forge Life Ins. Co., 204 S.W.3d 758, 772 (Tenn. 2006); see Shouse v. Otis, 448 S.W.2d 673, 677
(Tenn. 1969). To prove this causation, United Allergy relies on a multistep chain of events. The
Center’s agents (most notably, DeLozier) allegedly lobbied Amerigroup and other insurers to
investigate primary-care physicians who offered allergy-care services. This lobbying allegedly
led Amerigroup and the other insurers to audit the physicians. The audits, in turn, caused
Amerigroup and the other insurers to deny the physicians’ claims and to seek recoupment for
paid claims. Finally, the lack of reimbursement (plus the increased scrutiny) from Amerigroup
and the other insurers caused all 60 clinics to miss payments of the fees they owed United
Allergy.
This chain of events likely would not have allowed a reasonable jury to find that the
Center qualified as a but-for cause of the alleged breaches—let alone a substantial factor in
bringing them about. Most notably, the evidence shows that TennCare and Amerigroup had
independent concerns with excessive allergy-care billing by primary-care physicians separate
from anything the Center said. United Allergy, for example, identifies no evidence to suggest
that the Center (or DeLozier) caused TennCare to conduct its 2015 investigation into allergy-care
billing or to make its recommendations to reduce the reimbursement for this care because of
physician abuses. Mem., R.275-1, PageID 10144–50. Likewise, no evidence suggests that the
Center even knew of (let alone identified) the subcontract issue on which Amerigroup primarily
relied to deny the claims of physicians. See United Biologics, 2024 WL 770640, at *13 n.15. So
how could the Center have caused any of these subcontract-based denials? More generally,

-- 35 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 36
United Allergy does not identify evidence that the Center successfully convinced an insurer to
audit even a single primary-care physician. It instead relies on the Center’s generic lobbying
efforts. But we find it too “speculative” to connect those generic efforts all the way through to
any specific late payment by any specific physician. Naifeh, 204 S.W.3d at 772.
United Allergy has both factual and legal responses. Factually, it relies on an email chain
from 2015 among the Center’s “marketing managers,” including DeLozier. Appellant’s Br. 41.
In this chain, DeLozier bemoaned that United Allergy’s model encouraged physicians “to test
everyone” for allergies even though only about a third of patients need testing. Email, R.352-11,
PageID 20623. DeLozier also claimed that he had “many examples” of primary-care physicians
misdiagnosing nonallergic patients with allergies. Id. He suggested that the Center should
encourage insurers like Amerigroup to conduct “medical necessity audits” of primary-care
physicians because he believed the physicians would flunk these audits, which would “cut
[United Allergy] out of [the] pic[.]” Id. United Allergy also cites emails and notes from
DeLozier’s meetings with insurers that discussed these topics. See, e.g., Notes, R.299-5, PageID
15930; Email, R.299-6, PageID 16165; Mahler Dep., R.299-14, PageID 17244–53. Yet United
Allergy does not connect this evidence through the chain of causation that it hypothesizes. In
other words, it identifies no evidence that the Center successfully lobbied an insurer to perform a
medical-necessity audit of any physician that the insurer “would not have” otherwise audited on
its own initiative. Jenkins, 515 S.W.3d at 852. And it identifies no evidence that DeLozier’s
actions led any insurer to wrongly deny payments that the insurer “would not have” otherwise
denied. Id.
United Allergy also points to evidence that the Center tried to discourage a physician (Dr.
Christopher Climaco) from contracting with United Allergy in 2015. Appellant’s Br. 12, 43;
Email, R.292-5, PageID 15911–15. Yet Climaco ended up contracting with United Allergy
anyway. And this pre-contract evidence about events in 2015 does nothing to show that the
Center somehow caused Climaco’s clinic (Putnam County Pediatrics) to breach its contract with
United Allergy some five years later in 2020. McMahon Decl., R.299-12, PageID 16958.

-- 36 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 37
Legally, United Allergy notes that proximate causation does not require a party to “be the
sole cause” of a plaintiff’s injury. Hale, 166 S.W.3d at 718. True enough. But it does require
the party to be “a cause.” Id. And United Allergy’s evidence would not permit a reasonable
person to find that the Center caused any primary-care physician to pay any invoice late. See
Naifeh, 204 S.W.3d at 772. That “fatal flaw” dooms its claim. Jenkins, 515 S.W.3d at 853.
B. Tortious Interference with Business Relations
Tennessee courts also recognize the separate tort of intentional interference with business
relationships. See Trau-Med of Am., Inc. v. Allstate Ins., 71 S.W.3d 691, 701 (Tenn. 2002). Yet
this tort has a “confined scope.” BNA Assocs. LLC v. Goldman Sachs Specialty Lending Grp.,
L.P., 63 F.4th 1061, 1064 (6th Cir. 2023). Unlike a tortious-interference claim (which requires a
breach of contract), this tort covers both early business relationships that have yet to blossom
into binding contracts and continuing at-will relationships that will never produce binding long-
term commitments. See id. To prove this distinct claim, a plaintiff must show five things. See
Trau-Med, 71 S.W.3d at 701. The plaintiff must have had either an “existing business
relationship with specific third parties” or a “prospective” business “relationship” “with an
identifiable class of third persons[.]” Id. The defendant must have known of this relationship.
Id. The defendant must have acted with an intent to cause the relationship to end. Id. The
defendant must have harbored an “improper motive” or used “improper means” to end the
relationship. Id. And the plaintiff must have suffered an injury “resulting from” the defendant’s
interfering actions. Id.
Amerigroup asserts that this claim fails at the outset because United Allergy did not
present evidence to establish the required prospective relationship with an “identifiable class” of
physicians. United Allergy could not pursue this claim for breaches of existing contracts with
physicians. See BNA Assocs., 63 F.4th at 1064. So it had to point to an “identifiable class” of
physicians with whom it had a “prospective” (that is, expected) contractual relationship at the
time of the interference. Trau-Med, 71 S.W.3d at 701. And United Allergy does not dispute the
district court’s conclusion that it cannot list every physician in Tennessee as its “identifiable
class” of potential contract partners. See United Biologics, 2024 WL 770640, at *17.

-- 37 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 38
United Allergy instead claims it had an expected relationship with all physicians whom it
had “attempted to contract with” in some way in the past, whether by visiting their office or by
handing them a business card at a tradeshow. McMahon Dep., R.275-12, PageID 11836–37.
And it produced a spreadsheet that listed all these physicians. Does this spreadsheet satisfy the
“identifiable class” requirement? Trau-Med, 71 S.W.3d at 701. We think not. The Tennessee
courts have not provided much guidance on this element. When recognizing the tort claim,
though, the Tennessee Supreme Court broadly examined caselaw from other jurisdictions. See
id. at 699–701. And this caselaw typically requires plaintiffs to establish with “close certainty”
that they would have entered the contractual relationship, so a “mere hope of a contract” falls
short. United Educ. Distribs., LLC v. Educ. Testing Serv., 564 S.E.2d 324, 329–30 (S.C. Ct.
App. 2002) (citing cases); see Roy Allan Slurry Seal, Inc. v. Am. Asphalt S., Inc., 388 P.3d 800,
807–08 (Cal. 2017); Gieseke ex rel. Diversified Water Diversion, Inc. v. IDCA, Inc., 844 N.W.2d
210, 221–22 & n.10 (Minn. 2014); Ethan Allen, Inc. v. Georgetown Manor, Inc., 647 So.2d 812,
814–15 (Fla. 1994). The notion that United Allergy had a prospective contractual relationship
with a physician merely because a United Allergy salesperson had stopped by the physician’s
office at some point in the past strikes us as too “speculative” to support this tort. United Educ.
Distribs., 564 S.E.2d at 330.
That said, the district court found this element met based on a narrower class: the
physicians with whom United Allergy had contracted in the past. See United Biologics, 2024
WL 770640, at *17. We find this claim debatable because some state courts have held that
“[t]he mere hope that some of [a plaintiff’s] past customers may choose to buy again cannot be
the basis for a tortious interference claim.” Ethan Allen, 647 So.2d at 815. On the other hand,
Tennessee courts have suggested that an identifiable class can exist for those with whom
plaintiffs have an existing contractual relationship (say, currently contracted physicians) if the
plaintiffs allege interference with “future contractual relationship” between these parties. Clear
Water Partners, LLC v. Benson, 2017 WL 376391, at *7 (Tenn. Ct. App. Jan. 26, 2017). And
the Restatement suggests that the tort might reach interference with “a contract terminable at
will” (like United Allergy’s contracts with physicians) if the defendant’s interference causes the

-- 38 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 39
third party to end the at-will contract (without breaching it). Restatement (Second) of Torts
§ 766B cmt. c.
To avoid these debates, we will assume that the physicians with whom United Allergy
had previously contracted and those with whom it had an ongoing at-will relationship could
qualify as the identifiable class. The problem for United Allergy? Once we identify the class in
this way, its claims fail for the same reasons that its tortious-interference-with-contract claims
fail: partially on motive grounds (as to Amerigroup) and partially on causation grounds (as to the
Center).
1. Amerigroup. United Allergy has not shown that Amerigroup acted with an “improper
motive” or used “improper means” for the same reasons that it failed to show Amerigroup’s
malice. Trau-Med, 71 S.W.3d at 701. This result follows from the reality that this tort provides
less protection to business relationships than the protection provided by the tort that bars a party
from intentionally inducing a breach of contract. See Watson’s Carpet & Floor Coverings, Inc.
v. McCormick, 247 S.W.3d 169, 177 (Tenn. Ct. App. 2007). One party’s efforts to take
customers from another party is the essence of a free market, so courts have refused to interpret
the tort in a way that would “prohibit or undermine [a party’s] ability to contract freely and
engage in competition.” BNA Assocs., 63 F.4th at 1065 (citation omitted). To establish the
defendant’s improper motive, then, a plaintiff must show that the defendant acted with the
“predominant purpose” of injuring the plaintiff. Trau-Med, 71 S.W.3d at 701 n.5. And to
establish the defendant’s use of “improper means,” the plaintiff must show things like the
violation of existing laws or distinct torts. See id.
As we have said, however, Amerigroup did not act with an improper motive because it
investigated the physicians with whom United Allergy had contracted “to protect” TennCare and
its public funds. Mefford, 354 S.W.2d at 827 (citation omitted). And Amerigroup did not use
improper means because its reasonable interpretation of its contracts with those physicians
“justified” the complained-of investigations. Riggs, 879 S.W.2d at 852.
2. The Center. Likewise, United Allergy has not shown that the Center caused
physicians to terminate (or refuse to renew) their at-will contracts with United Allergy for the

-- 39 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 40
same reason that it has not shown that the Center caused the physicians to breach those contracts.
To prove this tort, United Allergy must show that the claimed harms “result[ed] from” improper
actions attributable to the Center. Trau-Med, 71 S.W.3d at 701. We read this language as
incorporating the same cause-in-fact and legal-cause requirements that the Tennessee courts
impose in common-law tort suits. See Cotten, 576 S.W.3d at 638. And United Allergy points us
to no evidence to suggest that the Center’s actions were a but-for cause (let alone a substantial
factor) in any physician’s decision to terminate a contract or refuse to renew one. See id.
C. Civil Conspiracy
This conclusion leaves United Allergy’s civil-conspiracy claim. To establish a
conspiracy, a plaintiff must prove that at least two actors shared a “common scheme” to carry out
either an “unlawful” goal or a lawful goal using “unlawful means” and that the agreed-on actions
injured the plaintiff. Trau-Med, 71 S.W.3d at 703. Yet this type of claim does not qualify as a
standalone tort. See Watson’s Carpet, 247 S.W.3d at 186. Rather, it qualifies as a method to
hold one conspirator liable for the actions of the others on vicarious-liability grounds. See Trau-
Med, 71 S.W.3d at 703. So a conspiracy to complete a lawful act in a lawful way does not create
any liability. See Forrester v. Stockstill, 869 S.W.2d 328, 330 (Tenn. 1994). And plaintiffs must
establish that the conspirators completed a “predicate tort” to hold them liable. Watson’s Carpet,
247 S.W.3d at 186. The district court held that United Allergy’s civil-conspiracy claim failed on
this ground because it did not establish that Amerigroup or the Center committed a tort against it.
See United Biologics, 2024 WL 770640, at *19. As far as we can tell, United Allergy does not
dispute that court’s conclusion that its conspiracy claim necessarily fails if its tortious-
interference claims cannot survive. See Appellant’s Br. 54–58. We thus find any contrary
reasoning forfeited. See Blick v. Ann Arbor Pub. Sch. Dist., 105 F.4th 868, 884 (6th Cir. 2024).
United Allergy instead argues that the district court overlooked its claim that the two
Blue Cross entities joined the conspiracy. If these Blue Cross entities committed torts against
United Allergy as part of a conspiracy, the conspiracy allegations would allow United Allergy to
hold Amerigroup and the Center liable for those torts. See Trau-Med, 71 S.W.3d at 703. United
Allergy is correct as a matter of law. But it is incorrect as a matter of fact. United Allergy’s

-- 40 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 41
appellate briefing does not elsewhere adequately explain why the conduct of these BlueCross
entities met all the required elements of its two tortious-interference claims. So it forfeited these
claims too. See Wilgar Land Co. v. Dir., Off. of Workers’ Comp., 85 F.4th 828, 842 (6th Cir.
2023).
We affirm.

-- 41 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 42
__________________
CONCURRENCE
__________________
KETHLEDGE, Circuit Judge, concurring. I join the court’s opinion, which offers a
careful synthesis of the relevant Supreme Court caselaw. For the reasons that Judge Murphy so
ably explains, I agree that the existing caselaw directs—albeit by analogy—the outcome that we
reach here. So far as I can tell, however, that result serves to harm consumer welfare rather than
advance it.
United Allergy’s complaint plausibly alleges that, before 2013, the market for allergen-
immunotherapy services in Tennessee was woefully undersupplied. Many patients in need of
those services did without; others drove long distances to receive them at the defendant Center,
which dominated the market and faced little competition. But the price signal did its work: in
2013 United Allergy entered this market with an innovative package of services that enabled
primary-care physicians to provide allergen-immunotherapy services directly to their patients.
As a result—with this new supplier—rates came down, access to these services became more
convenient, and more patients actually obtained them. But that created new competition for the
Center, and more claims for the defendant insurers to pay (on a flat-fee contract with TennCare,
no less). And so, the complaint alleges in detail, the Center and the insurers coordinated a
response—in which the insurers proceeded to audit, hassle, and otherwise deny payment to
physicians who had contracted with United Allergy to provide these services to patients in
Tennessee. That kind of campaign is what Judge Bork called a “disguised naked boycott”—
disguised, because it cloaks the refusal to deal in the exercise of some regulatory power (here,
the insurers’ power to review claims for payment). Robert H. Bork, The Antitrust Paradox 335–
37 (1978). And the result of that boycott, eventually, was the departure of United Allergy from
this market and a return to the former, undesirable status quo.
Thus, the complaint plausibly alleges, these defendants successfully conspired to eject a
new and more efficient supplier from a market that had been badly undersupplied before.
True—as a matter of strict, mechanical causation—the insurers’ boycott affected the physicians

-- 42 of 43 --

No. 24-5153 Academy of Allergy & Asthma et al. v.
Amerigroup Tenn., Inc. et al.
Page 43
directly, and United Allergy indirectly. Unlike the harm to a second-hand buyer in Illinois Brick,
however, the damage to United Allergy was not collateral. Quite the contrary: the ejection of
United Allergy from this market was the very object of the defendants’ scheme. The harms for
which United Allergy seeks redress were harms that the defendants specifically intended. The
parties that suffered collateral damage, rather, were the patients—who must again travel farther
and pay more for services at the Center, or go without treatment at all.
The goal of antitrust law is to advance consumer welfare. See, e.g., Brooke Group Ltd. v.
Brown & Williamson Tobacco Corp., 509 U.S. 209, 221 (1993); ProMedica Health System, Inc.
v. F.T.C., 749 F.3d 559, 571 (6th Cir. 2014); 2B Areeda ¶ 100 at 4 (“the principal objective of
antitrust policy is to maximize consumer welfare by encouraging firms to behave
competitively”); cf. Reiter v. Sonotone Corp., 442 U.S. 330, 343 (1979) (“Congress designed the
Sherman Act as a ‘consumer welfare prescription’”) (quoting Bork, The Antitrust Paradox 66
(1978)). I appreciate the Supreme Court’s concerns about allowing parties harmed indirectly to
bring antitrust claims. And legal rules must be general, rather than crafted to reach an outcome
in a particular case. But the Court’s concerns must be strong indeed, I suggest, to leave without
a remedy the pattern of conduct alleged here.

-- 43 of 43 --